Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Ritz

Showing results (211-220 of 315) with videos related to

Pageof 32
Sort By:
Haematologica|April 29, 2022
Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantationBenedetta Rambaldi, Haesook T Kim, Yohei Arihara, et al.
The New England Journal of Medicine|December 2, 2011
Interleukin-2 and regulatory T cells in graft-versus-host diseaseJohn Koreth, Ken-ichi Matsuoka, Haesook T Kim, et al.
The New England Journal of Medicine|August 9, 2013
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathMark T Vander Lugt, Thomas M Braun, Samir Hanash, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2016
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseKenneth R Cooke, Leo Luznik, Stefanie Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma VaccinesJohn M Goldberg, David E Fisher, George D Demetri, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Science Advances|August 18, 2023
Cultivated autologous limbal epithelial cell (CALEC) transplantation: Development of manufacturing process and clinical evaluation of feasibility and safetyUla V Jurkunas, Jia Yin, Lynette K Johns, et al.
Blood|February 3, 2017
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapyTakeru Asano, Yusuke Meguri, Takanori Yoshioka, et al.
Science Translational Medicine|May 27, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myelomaAdam S Sperling, Benjamin A Derman, Sarah Nikiforow, et al.
Blood|January 29, 2010
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesisJulia A Brown, Kristen Stevenson, Haesook T Kim, et al.
Pageof 32

Showing results (211-220 of 315) with videos related to

Sort By:
Pageof 32
Haematologica|April 29, 2022
Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantationBenedetta Rambaldi, Haesook T Kim, Yohei Arihara, et al.
The New England Journal of Medicine|December 2, 2011
Interleukin-2 and regulatory T cells in graft-versus-host diseaseJohn Koreth, Ken-ichi Matsuoka, Haesook T Kim, et al.
The New England Journal of Medicine|August 9, 2013
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathMark T Vander Lugt, Thomas M Braun, Samir Hanash, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2016
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseKenneth R Cooke, Leo Luznik, Stefanie Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma VaccinesJohn M Goldberg, David E Fisher, George D Demetri, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Science Advances|August 18, 2023
Cultivated autologous limbal epithelial cell (CALEC) transplantation: Development of manufacturing process and clinical evaluation of feasibility and safetyUla V Jurkunas, Jia Yin, Lynette K Johns, et al.
Blood|February 3, 2017
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapyTakeru Asano, Yusuke Meguri, Takanori Yoshioka, et al.
Science Translational Medicine|May 27, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myelomaAdam S Sperling, Benjamin A Derman, Sarah Nikiforow, et al.
Blood|January 29, 2010
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesisJulia A Brown, Kristen Stevenson, Haesook T Kim, et al.
Pageof 32